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Abstract 
Bone adapts to the mechanical forces that it experiences.  Orthodontic tooth movement harnesses 
the cell- and tissue-level properties of mechanotransduction to achieve alignment and 
reorganization of the dentition.  However, the mechanisms of action that permit bone resorption 
and formation in response to loads placed on the teeth are incompletely elucidated, though 
several mechanisms have been identified.  Wnt/Lrp5 signaling in osteocytes is a key pathway 
that modulates bone tissue’s response to load.  Numerous mouse models that harbor knock-in, 
knockout, and transgenic/overexpression alleles targeting genes related to Wnt signaling point to 
the necessity of Wnt/Lrp5, and its localization to osteocytes, for proper mechanotransduction in 
bone.  Alveolar bone is rich in osteocytes and is a highly mechanoresponsive tissue in which 
components of the canonical Wnt signaling cascade have been identified.  As Wnt-based agents 
become clinically available in the next several years, the a major challenge that lies ahead will be 
to gain a more complete understanding of Wnt biology in alveolar bone so that 
improved/expedited tooth movement becomes a possibility.   
 
  
The emerging age of precision medicine is ushering in new opportunities to perform more 
refined and targeted procedures and therapies in a variety of health contexts.  The practice of 
orthodontic tooth movement is among those fields that will benefit significantly from precision 
medicine approaches, but full realization will require a more detailed understanding of the 
signaling events in the different tissues involved in the process, e.g., alveolar bone-associated 
osteocytes and periodontal ligament-associated fibroblasts and neurovascular support cells.  
Alveolar bone undergoes a highly coordinated and rapid reorganization (i.e., remodeling) during 
tooth movement which is governed, at least in part, by the local osteocyte population.  The 
stimulus driving alveolar bone remodeling during orthodontic tooth movement is, at the most 
basic level, the mechanical forces placed on the dentition by external hardware.  The altered 
mechanical environment induces biochemical changes in the local cell populations that 
ultimately facilitate tooth movement through tissue space.  These changes–collectively known as 
mechanotransduction—involve activation and inhibition of numerous pathways that coordinate 
to achieve an adapted structure.  One of the key pathways that skeletal cells use to facilitate 
mechanotransduction is the Wnt signaling pathway, which is gaining recognition as a key player 
in orthodontic tooth movement process.   
Wnt/Lrp5 signaling impacts bone mass and strength  
Our understanding of osteocyte mechanotransduction took a significant leap forward when the 
importance of Wnt signaling in bone was identified.  Prior to the turn of this century, research on 
the Wnt signaling cascade was confined largely to the cancer (e.g., tumor biology and 
proliferation) and developmental biology (e.g., axis patterning) fields.  However, two key 
clinical discoveries changed our view on where and how Wnt signaling is important in the body, 
bringing the skeleton into direct focus as a major Wnt-dependent system.  The first of these 
discoveries was the finding that loss-of-function mutations in the Wnt co-receptor Low density 
lipoprotein receptor-related protein 5 (LRP5) are a genetic cause of the rare, debilitating disease 
Osteoporosis Pseudoglioma (OPPG) (1).  Patients with OPPG can present clinically with bone 
mineral density (BMD) values that are approximately 5 standard deviations below age-matched 
normal values, resulting in frequent fractures and impaired mobility.  At around the same time, 
other groups reported that gain-of-function mutations in LRP5 are a genetic cause for endosteal 
hyperosteosis, a high bone mass (HBM) condition (2, 3).  These patients have BMDs that are 
approximately 5 standard deviations above normal, but their skeletons are relatively normal in 
shape, and they present with none of the clinical manifestations associated with other, osteoclast-
mediated sclerosing bone disorders (e.g., osteopetrosis).  Thus, within a few short years, a single 
Wnt co-receptor was identified as causative for two very different rare skeletal diseases, one 
associated with very high bone mass and the other associated with very low bone mass.  As 
LRP5 has no other well-characterized primary ligands beyond the Wnt family, these human 
genetic studies implicated Wnt signaling as a major regulator of bone metabolism.   
Wnt/Lrp5 signaling participates in mechanotransduction  
Shortly after the discoveries regarding LRP5’s role in regulating human skeletal properties, 
mouse models were developed to model the diseases in mice and open up experimental options 
not possible in human patients.  Mice with loss-of-function mutations in Lrp5 (i.e., “knockout”) 
recapitulate the low bone mass phenotype observed in human OPPG patients (Fig. 1A).  These 
mice have low BMD, compromised trabecular mass and architecture, reduced cortical bone size, 
and impaired biomechanical properties (4).  We became interested in the role of Wnt signaling in 
mechanotransduction, and began experimenting with mechanoresponsiveness in Lrp5-/- mice.  
We performed in vivo mechanical loading experiments, using the rodent ulnar loading model, to 
assess the ability of Lrp5-/- mice to respond anabolically to a simulated vigorous exercise session.  
In both male and female Lrp5-/- mice, load-induced bone formation was significantly impaired 
compared to control (wild-type; WT) mice (4) (Fig. 1B).  That conclusion was later confirmed 
by another group in an independently generated Lrp5 knockout model, using a different loading 
modality (tibia loading) (5).  Thus the experimental data are consistent in implicating Wnt 
signaling through Lrp5 as a crucial process for skeletal mechanotransduction. i.e., without Lrp5 
receptors, bone tissue cannot adapt properly to mechanical inputs.  Those observations might 
explain a portion of the low bone mass phenotype among OPPG patients, i.e., that these 
individuals are unable to respond to otherwise stimulatory mechanical signals, and consequently, 
bone properties never reach their appropriate size and strength. 
While the Lrp5 knockout models are useful for exploring the role of the Wnt/Lrp5 axis in bone 
metabolism and mechanotransduction, we were also interested to learn whether the gain-of-
function mutations in LRP5 found in several families with HBM might also confer improved 
mechanical signaling properties to the cell.  To this end, we generated two different knock-in 
mouse lines, harboring one of two different HBM-causing missense mutations in Lrp5—G171V 
and A214V.  Like the human patients that these mutations were modeled after, the HBM knock-
in mice exhibited high BMD, dramatically increased trabecular and cortical bone mass, and 
improved biomechanical properties (6).  More importantly, however, the gain-of-function mutant 
mice were more responsive to tibial loading than their WT littermates (Fig. 1C) (7).  In 
summary, mice with either loss- or gain-of-function mutations in Lrp5 exhibit altered load-
induced bone formation, suggesting that Lrp5 plays a major role in mechanotransduction 
signaling in bone. 
Osteocytes are the cell type of action for Wnt/Lrp5-mediated modulation of bone mass.   
While both the gain-of-function knock-ins, and the loss-of-function knockout, all model the 
phenotypes observed human patients with analogous LRP5 mutations (i.e., the mice and humans 
have altered Lrp5 expression globally), those mouse models do not reveal the specific cell 
type(s) of action that account for the Wnt-driven skeletal phenotypes.  To address this issue, cell-
selective deletion of Lrp5 or expression of Lrp5-HBM alleles in specific cell types can reveal the 
relative contributions of these cell types to the overall phenotype.  Mice with floxed Lrp5 alleles 
(Lrp5f/f), where recombination of the loxP sites results in a null allele, have a normal bone mass 
in the absence of Cre recombinase.  However, when crossed to mice that express Cre in 
osteocytes (Dmp1-Cre), the mice develop an early-onset osteopenic phenotype that mimics the 
global Lrp5-/- model (Fig 2A) (6).  Likewise, mice engineered with a Cre-inducible heterozygous 
gain-of-function missense mutation in Lrp5, where recombination of a floxed Neo cassette in one 
of the introns releases the HBM allele from its dormant state, have normal bone mass in the 
absence of Cre recombinase.  However, when crossed to mice that express Cre in osteocytes 
(Dmp1-Cre), the mice develop an early-onset hyperostosis phenotype that mimics the global 
Lrp5-HBM model (Fig 2B) (6).   Thus, the osteocyte-selective deletion of Lrp5 and expression 
of Lrp5-HBM both recapitulate the global knockout and knock-in models, respectively, 
suggesting that mutation of Lrp5 in the osteocyte population is sufficient to recapitulate the bone 
phenotype of body-wide mutation.  These data implicate the osteocyte as the cell type of action 
for Wnt/Lrp5-mediated signaling in the modulation of bone mass.   
Osteocytes are the cell type of action for Wnt/Lrp5-mediated mechanotransduction 
Given the discovery that Lrp5 signaling in the osteocyte population accounts for the skeletal 
effects of this receptor, we next evaluated whether Wnt/Lrp5-mediated mechanotransduction was 
localized to the osteocyte.  As described above, crossing Dmp1-Cre mice to Lrp5f/f mice deletes 
Lrp5 selectively in the osteocyte population.  When subjected to ulnar loading, these mice have a 
severe deficit in load-induced bone gain (8), much like the global Lrp5-/- mice (Fig. 3) (4).  
Because the osteocyte is a key cell type for Wnt/Lrp5-mediated mechanotransduction, we looked 
for cellular mechanisms that might control Lrp5 signaling specifically in osteocytes, potentially 
explaining the normal mode of action for the Lrp5 receptor in a typical mechanical signaling 
event.  Here, we looked for Wnt Lrp5 modulators that were enriched in osteocytes, and the most 
obvious molecule is sclerostin.  In the skeleton, sclerostin expression is localized largely to the 
osteocyte population, to the exclusion of other skeletal cells (9).  Moreover, loss of sclerostin 
either by mutations in the SOST coding sequence (10), or by deletion of downstream SOST 
enhancer regions (11), results in very high bone mass.  Those two attributes, in addition to the 
observation that sclerostin is a high-affinity Lrp5 antagonist (12), has fueled inquiries into 
whether sclerostin is a key mediator of Lrp5-mediated mechanotransduction.  Sclerostin 
transcript and protein levels are dramatically reduced by mechanical loading, and the degree of 
down-regulation is closely associated with strain magnitude (13).  Thus, a load-induced 
reduction in local sclerostin levels appears to be a reasonable explanation as to how Lrp5 
achieves activation during loading.  In that context, mechanical stimulation induces a down-
regulation of sclerostin protein, which releases Lrp5 from inhibition, and promotes Wnt local 
Wnt signaling through Lrp5.  If this model is true, it would require that sclerostin must undergo 
downregulation in order for mechanotransduction to occur.  Testing this hypothesis directly with 
a functional study is challenging but not impossible, in that it would require applying mechanical 
loading to a mouse model in which sclerostin levels could be maintained at a high level, even in 
the presence of a mechanical stimulus (which normally causes Sost downregulation).  Those 
experimental conditions were achieved by using the Dmp1-hSOST transgenic mouse model.  
This mouse harbors a transgene comprising a human SOST cDNA under the control of the 
mouse Dmp1 promoter (14).  The Dmp1 promoter is load-responsive in the positive direction, 
i.e., Dmp1 expression is increased in response to a mechanical stimulus (15).  In the Dmp1-
hSOST transgenic mouse, mechanical loading induces the predicted downregulation of 
endogenous Sost expression (as would occur in a WT mouse), but at the same time induces an 
upregulation of transgenic hSOST expression, due to a load-induced increase in Dmp1 promoter 
activity.  Therefore this mouse can maintain high levels of sclerostin protein even in the context 
of mechanical loading.  When subjected to ulnar loading, the Dmp1-hSOST exhibits a nearly 
complete lack of mechanoresponsiveness (Fig. 4), which phenocopies the Lrp5-null 
mechanoresponsiveness (14).  In summary, numerous functional studies suggest that osteocyte 
Wnt/Lrp5 signaling is crucial for skeletal mechanotransduction, and the process appears to be 
regulated by the secreted Lrp5 antagonist sclerostin.   
More recently, sclerostin-mediated antagonism of Lrp5 appears to require a “facilitator” protein, 
without which the full inhibitory effects of sclerostin are not achieved.  The facilitator protein 
has been identified as Lrp4 (16), another LDL-like family member that has important functions 
in the neuromuscular junction (17).  Whether Lrp4 is involved in mechanotransduction, i.e., by 
altering the availability or localization of sclerostin during a mechanical loading event, is 
unknown.  Lrp4 has a role in tooth development (18, 19), but its function in orthodontic tooth 
movement (or generalized skeletal mechanotransduction) are not known.   
Wnt-mediated signaling in orthodontic tooth movement 
It is clear that osteocytic Wnt signaling plays a major role in skeletal mechanotransduction, but 
most of those insights come from the study of cortical and trabecular bone in the limbs.  Alveolar 
bone is rich with osteocytes, but less is known about the specific role of Wnt signaling in 
orthodontic tooth movement per se.   However, accumulating data suggests that Wnt signaling is 
also important in alveolar bone for tooth movement.  In mice subjected to tooth movement via 
and open-coil spring, Lrp5 and Fzd4 (a Wnt co-receptor) were upregulated in the periodontium 
near alveolar bone (20).  In addition, the downstream canonical mediator β-catenin was also 
activated in the same tissues by tooth movement.  Moreover, Lrp5-HBM mice exhibit an 
increase in alveolar bone formation, and narrowing of the PDL space (21).  Interestingly, in the 
alveolar bone surrounding a tooth engaged in orthodontic tooth movement, Sost expression 
increases on the compression side and is briefly downregulated on the tension side (22).  These 
dynamics are consistent with an increase in resorption in the area where the tooth is prompted to 
move (high sclerostin), and an increase in bone formation in the wake of the moving tooth (low 
sclerostin).  It is likely that in the near future, Wnt-based therapies will be useful for facilitating 
more rapid orthodontic tooth movement, but more focused experiments are required to better 
understand the biology that is specific to alveolar bone.  Currently, Wnt pathway activators (e.g., 
Sost antibody) and Wnt pathway inhibitors (e.g., small molecule Porcupine inhibitors) are 
currently under consideration by the FDA for clinical use.  If these agents are successfully 
brought to market, an expanding toolbox of Wnt modulation will be available to the orthodontic 
community.  Harnessing those tools to achieve a more favorable orthodontic outcome will 
remain a challenge until the basic science of Wnt specifically in alveolar bone and the PDL is 
more thoroughly elucidated.      
  
Figure Legends: 
Figure 1: Mice with global homozygous loss-of-function mutations in the Lrp5 receptor have 
(A) reduced whole body bone mineral content per unit body mass (BMC/BM), and reduced 
trabecular and cortical bone mass in the femur diaphysis and metaphysis. (B) Mechanical 
stimulation of the ulna in Lrp5-/- mice results in significantly lower periosteal relative bone 
formation rates per unit bone surface (rBFR/BS) compared to wild type (Lrp5+/+) and 
heterozygous mice (Lrp5+/-), at strains greater than 1200 microstrain.  (C) Mechanical 
stimulation of the tibia in mice with homozygous global high bone mass-causing missense 
mutations in Lrp5 results in significantly greater periosteal rBFR/BS compared to wild type 
(Lrp5+/+) mice. 
Figure 2: Distal femur metaphyseal µCT reconstructions reveal that (A) mice with Lrp5-HBM 
alleles activated only in Dmp1-expressing cells (Dmp1-Cre-mediated activation of dormant 
Lrp5-HBM alleles [+/AN]) recapitulate the HBM phenotype of mice with globally expressed 
HBM alleles (+/A).  (B) Mice with floxed loss of function Lrp5 alleles recombined only in 
Dmp1-expressing cells exhibit a low bone mass phenotype, similar to that observed in mice 
carrying global loss-of-function alleles.   
Figure 3: Mice with osteocyte-selective deletion of Lrp5 exhibit reduced responsiveness to ulnar 
loading than Cre-negative mice.  (Left) Histological photomicrographs of the loaded and 
nonloaded ulnae in Cre-positive and Cre-negative mice, illustrating the paucity of labeling in 
Cre-positive mice.  (Right) Quantification of periosteal relative bone formation rates per unit 
bone surface (rBFR/BS) in the ulnae was significantly reduced in Cre-positive mice.   
Figure 4: Mice carrying the Dmp1-hSOST transgene do not respond to mechanical stimulation 
of the ulna.  (Left) Histological photomicrographs of the loaded and nonloaded ulnae in 
transgenic and nontransgenic mice, illustrating the paucity of labeling in transgenic mice. (Right) 
Quantification of periosteal relative bone formation rates per unit bone surface (rBFR/BS) in the 
ulnae was significantly reduced in transgenic mice.   
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